Initial Therapy: When Progression Occurs

Tecentriq plus Cabometyx conferred no overall survival benefit when compared with chemotherapy, a study showed.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

I wrote this heart-felt poem after watching my father pass away from stage 4 lung cancer.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Writing poetry helped me process the grief of losing my mom to metastatic lung cancer.

Some patients with limited-stage small cell lung cancer experienced overall survival benefits and progression-free survival via treatment with Imfinzi.